Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers ; day:25 ; month:5 ; year:2024 ; pages:1-12
GeroScience ; (25.5.2024), 1-12
- Creator
-
Oyebanji, Oladayo A.
Sundheimer, Nicholas
Ragavapuram, Vaishnavi
Wilson, Brigid M.
Abul, Yasin
Gravenstein, Stefan
Bosch, Jürgen
King, Christopher L.
Canaday, David H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11357-024-01215-y
- URN
-
urn:nbn:de:101:1-2408051132027.259038038248
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oyebanji, Oladayo A.
- Sundheimer, Nicholas
- Ragavapuram, Vaishnavi
- Wilson, Brigid M.
- Abul, Yasin
- Gravenstein, Stefan
- Bosch, Jürgen
- King, Christopher L.
- Canaday, David H.
- SpringerLink (Online service)
Other Objects (12)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Low but recoverable markers of humoral immune response to BNT162b2 in elderly LTCF residents five to seven months after two-dose vaccination
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Low but recoverable markers of humoral immune response to BNT162b2 in elderly LTCF residents five to seven months after two-dose vaccination
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Low but recoverable markers of humoral immune response to BNT162b2 in elderly LTCF residents five to seven months after two-dose vaccination
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response